Skip to main
EW
EW logo

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 39 analyst ratings
Buy
Strong Buy 26%
Buy 36%
Hold 36%
Sell 3%
Strong Sell 0%

Bulls say

Edwards Lifesciences is poised for significant growth, with a projected revenue of $5.83 billion in 2025, reflecting a 9.2% year-over-year underlying increase, including a $4.27 billion contribution from transcatheter aortic valve replacement (TAVR) sales. The company's performance in Q4 indicates strong demand, with TAVR sales reaching $1.04 billion, marking a 9.3% year-over-year underlying growth, while TMTT sales showcased remarkable growth of 85% year-over-year on an ex-FX basis. Furthermore, Edwards Lifesciences anticipates the global transcatheter mitral and tricuspid therapies (TMTT) market will expand to $5 billion, highlighting robust long-term growth potential in this segment.

Bears say

Edwards Lifesciences is facing a negative outlook due to projected Q1 2025 growth rates for total company sales and TAVR technologies falling below the low end of the firm's guidance ranges, largely attributed to having one less selling day in the quarter. Additionally, multiple external factors, such as macroeconomic conditions, competition, and challenges in market penetration, are expected to hinder revenue growth, while foreign exchange impacts are anticipated to create a significant headwind of approximately $130 million. Overall, these dynamics are contributing to a projection suggesting a decline in stock performance, as indicated by the downside scenario analysis based on future price-to-earnings ratios.

Edwards Lifesciences (EW) has been analyzed by 39 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 39 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.49, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.49, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.